Nanoparticulate drug delivery to the reticuloendothelial system and to associated disorders

Nanoparticulates as Drug Carriers

Volumn , Issue , 2006, Pages 463-480

  Basu, Mukul Kumar ^a   Lala, Sanchaita ^a  

^a NONE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

NANO PARTICULATES; RETICULOENDOTHELIAL SYSTEMS;

DRUG DELIVERY;

EID: 79953748412     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1142/9781860949074_0021     Document Type: Chapter

References (46)

1. Moghimi SM and Patel HM (1998) Serum mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system - The concept of tissue specificity. Adv Drug Del Rev 32:45-60.
2. Moghimi SM and Hunter AC (2001) Recognition by macrophages and liver cells of opsonized phospholipid vesicles and phospholipid head groups. Pharm Res 18(1):1-8.
3. Absolom D (1986) Opsonins and dysopsonins - An overview. Meth Enzymol 132:323-326.
4. Hostetter MK, Krueger RA and Schmelling DJ (1984) The biochemistry of opsonization: Central role of the reactive thiolester of the third component of complement. J Infect Dis 150:653-661.
5. Ryder KW Jr, Kaplan JE and Saba TM (1975) Serum calcium and hepatic Kupffer cell phagocytosis. Proc Soc Exp Biol Med 149:163-167.
6. Moghimi SM and Patel HM (1990) Calcium as a possible modulator of Kupffer cell phagocytic function by regulating liver specific opsonic activity. Biochim Biophys Acta 1028(3):304-308.
7. Moghimi SM and Patel HM (1989) Serum opsonins and phagocytosis of saturated and unsaturated phospholipid liposomes. Biochim Biophys Acta 984(3):384-387.
8. Sinha J, Raay B, Das N, Medda S, Garai S, Mahato SB and Basu MK (2002) Bacopasaponin C: Critical evaluation of antileishmanial properties in various delivery modes. Drug Del 9:55-62.
9. Sarkar S, Mandal S, Sinha J, Mukhopadhyay S, Das N and Basu MK (2003) Quercetin: Critical evaluation as an antileishmanial agent in vivo. J Drug Targ 10:573-578.
10. Lala S, Pramanick S, Mukhopadhyay S, Bandyopadhyay S and Basu MK (2004) Harmine: Evaluation of its antileishmanial properties in various delivery systems. J Drug Targ 12(3):165-175.
11. Stolnik S, Heald CR, Neal J, Garnett MC, Davis SS, Ilium L, Purkis SC, Barlow RJ and Gellert PR (2001) Poly-lactide poly(ethylene glycol) miceller-like particles as potential drag carriers: Production, colloidal properties and biological performance. J Drug Targ 95(5):361-378.
12. Roser M, Fischer D and Kissel T (1998) Surface-modified biodegradable albumin nano- and microspheres II. Effect of surface charges on in vitro phagocytosis and biodistribution in rats. Eur J Pharm Biopharm 46(3):255-263.
13. Luck M, Paulke BR, Schroder W, Blunk T and Muller RH (1991) Analysis of plasma protein adsorption on polymeric nanoparticles with different surface characteristics. J Biomed Mater Res 39(3):478-485.
14. Moghimi SM, Porter CJH, Muir IS, Ilium L and Davis SS (1991) Non-phagocytic uptake of intravenously injected microspheres in rat spleen: Influence of particle size and hydrophilic coating. Biochem Biophys Res Commun 177:861-866.
15. Moore A, Weissleder R and Bogdanov A Jr (1997) Uptake of dextran-coated monocrystalline iron oxides in tumor cells and macrophages. J Magn Reson Imaging 7(6):1140-1145.
16. Leroux JC, Gravel P, Balant L, Volet B, Anner BM, Allemann E, Doelker E and Gurny R (1994) Internalization of poly-(D,L-lactic acid) nanoparticles by isolated human leucocytes and analysis of plasma proteins adsorbed onto the particles. J Biomed Mater Res 28(4):471-481.
17. 14CJ-poly (lactic acid) nanoparticles coated with albumin after parenteral administration to rats. Biomaterials 13(15):1093-1102.
18. Norman ME, Williams P and Ilium L (1993) Influence of block copolymers on the adsorption of plasma proteins to microspheres. Biomaterials 14(3):193-202.
19. Armstrong TI, Moghimi SM, Davis SS and Ilium L (1997) Activation of the mononuclear phagocyte system by poloxamine 908: Its implication for targeted drug delivery. Pharm Res 14(11):1629-1633.
20. Vandorpe J, Schact E, Dunn S, Hawley A, Stolnik S, Davis SS, Garnett MC, Davies MC and Ilium L (1997) Long-circulating biodegradable poly-(phosphazene) nanoparticles surface-modified with poly-(phosphazene)-poly(ethylene oxide) copolymer. Biomaterials 18(17):1147-1152.
21. Neal JC, Stolnik S, Garnett MC, Davis SS and Ilium L (1998) Modification of the copolymers poloxamer 407 and poloxamine 908 can effect the physical and biological properties of surface-modified nanospheres. Pharm Res 15(2):318-324.
22. Ilium L, Jacobson LO, Muller LH, Mok E and Davis SS (1987) Surface characteristics and the interaction of colloidal particles with mouse peritoneal macrophages. Biomaterials 8(2):113-117.
23. Moghimi SM, Hawley AE, Christy NM, Gray T, Ilium L and Davis SS (1994) Surface engineered nanospheres with enhanced drainage into lymphatics and uptake by macrophages of the regional lymph nodes. FEBS Lett 344(1):25-30.
24. Hawley AE, Ilium L and Davis SS (1997) Lymph node localization of biodegradable nanospheres surface modified with poloxamer and poloxamine block copolymers. FEBS Lett 400(3):319-323.
25. Hawley AE, Ilium L and Davis SS (1997) Preparation of biodegeradable, surface-engineered PLGA nanospheres with enhanced lymphatic drainage and lymph node uptake. Pharm Res 14(5):657-661.
26. Ilium L, Church AE, Butter worth MD, Arien A, Whetstone J and Davis SS (2001) Development of systems for targeting the regional lymph nodes for diagnostic imaging: In vivo behavior of colloidal PEG-coated magnetite nanospheres in the rat following interstitial administration. Pharm Res 18(5):640-645.
27. Porter CJ, Moghimi SM, Ilium L and Davis SS (1992) The poly oxyethy-lene/polyoxypropylene block co-polymer poloxamer-407 selectively redirects intravenously injected microspheres to sinusoidal endothelial cells of rabbit bone-marrow. FEBS Lett 305(1):62-66.
28. Araujo L, Lodenberg R and Kreuter J (1999) Influence of the surfactant concentration on the body distribution of nanoparticles. J Drug Targ 6:373-385.
29. Chen Y, Xou Z, Zheng D, Xia K, Zhao Y, Liu T, Long Z and Xia J (2003) Sodium chloride modified silica nanoparticles as a non-viral vector with a high efficiency of DNA transfer into cells. Curr Gene Ther 3:273-279.
30. Medda S, Jaisankar P, Manna RK, Pal B, Giri VS and Basu MK (2003) Phospholipid microspheres: A novel delivery mode for targeting antileishmanial agent in experimental leishmaniasis. J Drug Targ 11(2):123-128.
31. Cui Z, Hsu CH and Mumper RJ (2003) Physical characterization and macrophage cell uptake of mannan-coated nanoparticles. Drug Dev Ind Phar 29(6):689-700.
32. Tyagi R, Lala S, Verma AK, Nandy AK, Mahato SB, Maitra A and Basu MK (2005) Targeted delivery of arjunglucoside I using surface hydrophilic and hydrophobic nanocarriers to combat experimental leishmaniasis. J Drug Targ 13:161-171.
33. Pandey R, Zahoor A, Sharma S and Khuller GK (2003) Nanoparticle encapsulated anti-tubercular drugs as a potential oral drug delivery system against murine tuberculosis. Tuberculosis 83:373-378.
34. Pandey R and Khuller GK (2004) Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model. J Antimicrob Chemother 54:266-268.
35. Pandey R, Sharma A, Zahoor A, Sharma S, Khuller GK and Prasad B (2003) Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother 52:981-986.
36. Fusai T, Boulard Y, Durand R, Paul M, Bories C, Rivollet D, Astier A, Houin R and Deniau M (1997) Ultrastructural changes in parasites induced by nanoparticle-bound pentamidine in a Leishmania major/mouse model. Parasite 4:133-139.
37. Espuelus MS, Legrand P, Loiseau PM, Bories C, Barratt G and Irache JM (2002) In vitro antileishmanial activity of amphotericin B loaded in poly (epsilon-caprolactone) nanospheres. J Drug Targ 10:593-599.
38. Veerareddy PR, Vobalaboina V and Nahid A (2004) Formulation and evaluation of oil-in-water emulsions of piperine in visceral leishmaniasis. Pharmazie 59:194-197.
39. Cauchetier E, Paul M, Rivollet D, Fessi H, Astier A and Deniau M (2003) Therapeutic evaluation of free and nanocapsule-encapsulated atovaquone in the treatment of murine visceral leishmaniasis. Ann Trop Med Parasitol 97:259-268.
40. Gonzalez-Martin G, Merino I, Rodriguez-Cabezas MN, Torres M, Nunez R and Osuna A (1998) Characterization and trypanocidal activity of nifurtimox-containing and empty nanoparticles of polyethyl cyanoacrylates. J Pharm Pharmacol 50:29-35.
41. Lamprecht A, Ubrich N, Yamamoto H, Schafer U, Takeuchi H, Maincent P, Kawashima Y and Lehr CM (2001) Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J Pharmacol Exp Ther 299:775-781.
42. Bender AR, Von Briesen H, Kreuter J, Duncan IB and Rubsamen-Waigmani H (1996) Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency-virus infected human monocytes/macrophages in vitro. Antimicrob Agents Chemother 40:1467-1471.
43. Lodenberg R and Kreuter J (1996) Macrophage targeting of azidothymidine: A promising strategy for AIDS therapy. AIDs Res Hum Retroviruses 12:1709-1715.
44. Roy I, Mitra A, Moitra A and Mozumdar S (2003) Calcium phosphate nanoparticles as novel non-viral vectors for targeted gene delivery. Int J Pharm 250:25-33.
45. Mao HQ, Roy K, Troung-Le VL, Janes KA, Lin KY, Wang Y, August JT and Leong KW (2001) Chitosan-DNA nanoparticles as gene carriers: Synthesis, characterization and transfection efficiency. J Control Rel 70(3):399-421.
46. Aynie I, Vauthier C, Chacun H, Fattal E and Couvreur P (1999) Spongelike alginate nanoparticles as a new potential system for the delivery of antisense oligonucleotides. Antisense Nucleic Acid Drug Del 9:301-312.